Alzheimer's disease (ad) is a pathology with high socioeconomic impact corresponding to 1.70% of deaths in developed countries. It is estimated that 24.3 million people are affected and that 4.6 million new cases occur each year (WHO, 2005). In developed countries, AD is the 5th largest cause of death, corresponding to 168 thousand people/year (WHO, 2010). In the us, 10.9 mi people are unpaid caregivers. These caregivers are mostly family members close to the patient, which causes great emotional and financial impact to families as the disease progresses, leading to death. From the onset of the first symptoms to death, the progression of the disease is 8.5 to 11 years, with an average of 4 to 6 years of life (Alzheimer's Assoc., 2010). Estimated costs of ad treatment worldwide are $ 315 billion (pfizer®, inc., 2009).
Inhibit the enzyme ache to increase the cholinergic activity of the central nervous system, controlling the symptoms of alzheimer's disease in the areas of memory and learning. Through this mechanism it is also possible to control muscular paralysis caused by chemical or biological agents, Myasthenia gravis and scopolamine poisoning.
Agência Unesp de Inovação
Tel: +55 11 5627.0696